Threat to anti-VEGFs from Oraya's AMD device grows
This article was originally published in Scrip
Executive Summary
Oraya Therapeutics has reported more favorable data for its device designed to treat wet age-related macular degeneration (AMD) in a one-off procedure and which could potentially threaten drugs such as Roche/Novartis' market-leading anti-VEGF therapy Lucentis (ranibizumab).